Navigation Links
Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
Date:6/8/2009

President, Global Head, Novartis Oncology Development. "These latest data show an antitumor effect in lymphoma that support the rationale for a Phase III study of Afinitor to prevent relapse in patients with diffuse large B-cell lymphoma, where there is a significant unmet medical need."

Novartis has initiated PILLAR-2 (PIvotaL Lymphoma triAls of RAD001), a Phase III trial investigating adjuvant treatment with everolimus (RAD001) in poor-risk patients with DLBCL who achieved complete remission with first-line rituximab combined with chemotherapy. This worldwide study will evaluate the potential of everolimus to extend disease-free survival in patients with DLBCL. The longer a patient with DLBCL is in remission the higher their likelihood to remain disease-free. There is no approved therapy for the approximately 50% of patients who will relapse after achieving a complete response on initial treatment, demonstrating an important unmet need(6).

EHA study details

The proof-of-concept, open-label, single-arm, multicenter Phase II study was designed to assess the efficacy and safety of everolimus in patients with relapsed/refractory aggressive or indolent NHL or Hodgkin's disease whose disease progressed despite prior treatment. Patients had received a median of four prior therapies (between one and 15 therapies). The study included patients with T-cell non-Hodgkin's lymphoma, Hodgkin's disease, follicular lymphoma, mantle cell lymphoma, DLBCL and small lymphocytic lymphoma; all of whom had experienced disease progression despite prior treatment. The primary endpoint of the study is to assess ORR. Secondary endpoints include assessment of progression-free survival (PFS), overall survival, time to disease progression and the safety profile of Afinitor(1).

In the trial, everolimus showed anticancer activity across multiple types of lymphoma, including T-cell non
'/>"/>

SOURCE Novartis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... LAWRENCE, Mass. , Dec. 22, 2014 /PRNewswire/ ... a leading manufacturer of innovative dialysis products, announced ... (FDA) has cleared its System One™ to perform ... sleeping, known as home nocturnal hemodialysis. NxStage,s® System ... cleared by the FDA for this indication. ...
(Date:12/22/2014)... 2014 Research and Markets ( ... "Investment Analysis of the US Medical Device ... http://photos.prnewswire.com/prnh/20130307/600769 ... device sector identifies the key trends and rationale ... and mergers and acquisitions. The study ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals ... company focused on discovering, developing and commercializing innovative ... technologies, today issued the following open letter to ... , Dr. Med. Sc. Dear RXi ... a number of inaccurate statements posted on certain ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... Decision Resources, one of the world,s leading research ... that, through 2019, an expanding aging population and increases ... percent annual growth in the chronic obstructive pulmonary disease ... findings from the topic entitled Chronic Obstructive Pulmonary ...
... -- DALLAS, Texas, August 31, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Medicine Technology:An Expanding Aging Population and Increases in Diagnosis and Drug Treatment Will Fuel Steady 4.6 Percent Annual Growth in the Chronic Obstructive Pulmonary Drug Market 2The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 2The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 3The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 4The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 5The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 6The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 7The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 8The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 9
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International founder ... an 8 year battle with breast cancer. , ... her home in Woodland Hills California after an 8 ... , As the founder and volunteer President of ... championed many of today's greatest breakthroughs in restoring and ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... children with complex chronic illnesses can receive effective, less expensive ... with easy access to a team of dedicated health care ... to become seriously ill and need either hospitalization or a ... an enhanced medical home clinic at the University of Texas ...
(Date:12/25/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Among early ... treatment, less than half of one percent will eventually ... new analysis reveals. The finding comes from a ... between 1998 and 2007, and it suggests that the ... double what experts had previously thought. "The frequency ...
(Date:12/25/2014)... 2014 Thousands of transvaginal mesh lawsuits ... a number of multidistrict litigations currently underway in U.S. ... LLP reports. According to an Order issued on December ... Joint Status Conference in all of the proceedings on ... directed to submit a proposed agenda to the Court ...
(Date:12/25/2014)... Residents at Abernethy Laurels ... their generous spirit by providing holiday gifts to ... Network- Grandparents Raising Grandchildren program. , Following a ... largest Christmas tree on the campus of the ... of the Abernethy Village Association (AVA). Each holiday ...
Breaking Medicine News(10 mins):Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Retirement Community Residents Make Impact During Holiday Season 2
... their white counterparts to receive therapy for various kinds ... treatment, according to a study by researchers at Yale ... issue of the journal Cancer. , Prior research revealed ... Cary P. Gross, M.D., associate professor of medicine at ...
... OmniPod(R) Personal Diabetes Manager to Integrate DexCom ... Continuous Glucose Monitoring Technology, ... (Nasdaq: PODD ), the leader in wearable insulin ... Inc. (Nasdaq:,DXCM), a leading provider of continuous glucose monitoring ...
... -,A USA TODAY/ Discovery Health/Gallup Poll released today states ... also influence an,individual,s ability to lose weight and maintain ... Health/USA TODAY/Gallup poll include:, -- Nearly one in ... been a hindrance in their attempts to lose weight, ...
... Jan. 7, 2008 Dr. Joseph Ravenell, assistant professor ... received a Harold Amos Medical Faculty Development Award from ... his research for the next four years. , ... number of academic medicine faculty from historically disadvantaged ethnic, ...
... Spinal cord damage blocks the routes that the brain uses to send ... that the only way for injured patients to walk again was to ... the spinal cord. For the first time, a UCLA study shows ... to restore the cellular communication required for movement. , ...
... Prof. Allen Foster,announces that cbm has expanded its areas ... persons with visual loss., For the past 100 ... Blind Mission, has worked to prevent and treat,blindness and ... "The organization has decided that its purpose and ...
Cached Medicine News:Health News:Despite efforts, significant racial disparities in cancer therapy still exist 2Health News:Insulet Corporation and DexCom Announce Development Agreement 2Health News:Insulet Corporation and DexCom Announce Development Agreement 3Health News:Insulet Corporation and DexCom Announce Development Agreement 4Health News:Insulet Corporation and DexCom Announce Development Agreement 5Health News:Insulet Corporation and DexCom Announce Development Agreement 6Health News:New Poll Announces Link Between Friends and Family Influence and a Healthy Lifestyle 2Health News:New Poll Announces Link Between Friends and Family Influence and a Healthy Lifestyle 3Health News:Ravenell named recipient of grant from Robert Wood Johnson Foundation 2Health News:UCLA scientists restore walking after spinal cord injury 2Health News:UCLA scientists restore walking after spinal cord injury 3Health News:cbm Expanding its Mandate 2
... Lyphochek Immunoassay Plus Control provides the ... control in the world for monitoring ... eliminating the need for separate controls. ... added preservatives, it is suitable for ...
Lyphochek Immunology Plus Control is an assayed control for monitoring chemistry procedures that test for autoimmune, anemic, malignant, hepatic and nephrotic-disease states. Available in two levels....
... The Vidiera NsD Nucleic Sample Detection Platform ... post amplification. The new platform for ... capillary electrophoresis (CE), with software features that ... flexibility. Vidiera NsD has the capacity ...
... Sample Preparation Platform provides flexible, automated extraction ... can prepare up to 96 patient samples ... one half-hours, and performs onboard quantitation and ... minutes each. Based on Beckman Coulters ...
Medicine Products: